News archive

Read the latest news from the nanomedicine world.

Dear ETPN members, dear colleagues, here is some great news for our community:  University of Cambridge and University of Glasgow have decided to become new ETPN members, in the framework of the EPSRC IRC in Targeted Delivery for Hard-to-Treat Cancers.

EPSRC IRC in Targeted Delivery for Hard-to-Treat Cancers

The Engineering and Physical Sciences Research Council (EPSRC) Interdisciplinary Research Centre (IRC) in Targeted Delivery for Hard-to-Treat Cancers was established in October 2018. It comprises five leading universities (Cambridge, Imperial, UCL, Glasgow & Birmingham) alongside several partner institutions, and aims to develop new technologies capable of enhanced drug delivery for the treatment of four hard-to-treat cancers: mesothelioma, pancreatic cancer, and two types of brain cancer – glioblastoma & ependymoma.

The technologies being developed include injectable, self-healing and mechanically tuneable hydrogels, high capacity delivery vehicles with targeting capabilities, and implantable electrophoretic delivery devices

The approach

The IRC comprises clinicians, chemists and engineers working to develop, manufacture and characterize the vehicles/devices required to deliver therapeutics. We combine the work done within the universities with partner companies/institutions with expertise in the development of drug delivery technologies.

There are two research themes: (1) high capacity vehicles and injectable gels, (2) implantable devices. These are complimented by two crosscutting activities: validation and delivery & manufacturing.

Visit the website of the EPSRC IRC!

Welcome University of Cambridge and University of Glasgow!

We are honored and delighted to welcome these two new prestigious members of the ETPN. We look forward very much to seeing new partnerships forged with you.